- Market Capitalization, $K 131,072,168
- Shares Outstanding, K 2,624,593
- Annual Sales, $ 26,617 M
- Annual Income, $ 3,196 M
- 60-Month Beta 0.55
- Price/Sales 4.88
- Price/Cash Flow 15.43
- Price/Book 8.31
|Period||Period Low||Period High||Performance|
| || |
+0.67 (+1.36%)since 03/09/21
| || |
-0.92 (-1.81%)since 01/08/21
| || |
+5.28 (+11.82%)since 04/09/20
FDA delays decision on Pfizer (PFE), AbbVie (ABBV) and Lilly's (LLY) filings for JAK inhibitor candidates. AstraZeneca's (AZN) COVID-19 vaccine troubles continue.
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.
Gilead (GILD) obtains full approval for its breast cancer drug, Trodelvy, in the United States for metastatic triple-negative breast cancer.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHPT, GME, MARA, AZN, and NVDA.
European regulators find a possible link between AstraZeneca's (AZN) COVID-19 vaccine and rare blood clot events.
Oxford University pauses dosing in AstraZeneca's (AZN) COVID-19 vaccine study in children until U.K. regulator completes review of fresh rare blood clot events.
The global "depression treatment therapy market" size is expected to gain momentum backed by the increasing incidence of suicides and the growing number of psychiatrists that is likely to boost the adoption...
AstraZeneca has entered into a collaboration agreement with Massachusetts General Hospital (MGH), leveraging robust data and clinical best practices to create digital health solutions that address today's...
Emergent (EBS) receives additional $23 million from BARDA to support further expansion of manufacturing capacity for Johnson & Johnson's COVID-19 vaccine.
|Advisorshares Doubleline Value Equity ETF|
|IQ Healthy Hearts ETF|
|Flexshares Global ESG Impact Index|
|ESG Intl Stock Vanguard ETF|
|GS Activebeta International ETF|
|3rd Resistance Point||50.65|
|2nd Resistance Point||50.41|
|1st Resistance Point||50.17|
|1st Support Level||49.69|
|2nd Support Level||49.45|
|3rd Support Level||49.21|